Pharmaceutical companies are cautiously optimistic about their growth prospects under a potential second Trump administration. The industry hopes for a focus on reducing health-care costs, a bipartisan issue where Americans pay two-to-three times more for prescription drugs than people in other developed countries. Trump’s previous term saw efforts to link U.S. drug prices to lower international prices, but his new approach might emphasize cracking down on pharmacy benefit managers (PBMs) rather than directly targeting drug prices. PBMs are criticized for overcharging insurance plans, underpaying pharmacies, and not passing on savings to patients. The industry seeks reforms like breaking the link between drug list prices and PBM compensation, ensuring rebates reach patients, and increasing transparency in PBM practices. Despite these hopes, uncertainties remain, particularly with Robert F. Kennedy Jr.’s potential role in health policy, given his anti-vaccine stance. However, there’s alignment with Trump’s focus on chronic diseases and cancer, suggesting potential for collaboration in these areas.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
!["Pharma 4.0: The next destination of Pharmaceutical industry"(Caritas Pharma Talk-3) [Clear Video]](https://i.ytimg.com/vi/gi394n-u1IE/mqdefault.jpg)
